anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: PF-07304814
Trial phase: Phase 3
SMILES: [H][C@@]1(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)c2cc3c(OC)cccc3[nH]2)C(=O)COP(=O)(O)O)CCNC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: PF-07304814 250 mg per day for 5 days; administered as a constant rate IV infusion
Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion

PF-07304814: PF-07304814 is a phosphate ester prodrug of PF-00835231 (active moiety), a potent and selective inhibitor of the SARS-CoV-2 3CLpro.

Remdesivir: Antiviral agent
Eligibility criteria:
Inclusion Criteria: Refer to the master protocol (NCT04501978)

Exclusion Criteria: Refer to the master protocol (NCT04501978)

Additional Exclusion Criteria:

Participants with moderate to severe hepatic impairment (i.e. Child-Pugh class B or C) or acute liver failure.
Participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450 (CYP) 3A4 (see Section H6.3.4).
Patients will be excluded if taking drugs which have a narrow therapeutic window that are substrates of CYP3A4, including but not limited to: astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus, tacrolimus, and terfenadine.
Pregnant women
Nursing mothers
Women of child-bearing potential who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with men or practice appropriate contraception through 5 weeks of the study.
Men who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with women of child-bearing potential or to use barrier contraception through 5 weeks of the study.

Patients with a history of deep vein thrombosis or pulmonary thrombotic embolism*.

Prior to the initial futility assessment, which is performed when approximately 150 patients have been enrolled on PF-07304814 and 150 on placebo, patients with a history of deep vein thrombosis or pulmonary embolism will be excluded. These patients will be eligible for the trial if the initial futility assessment is passed by this agent, and if risk-benefit is favorable based on an assessment of available data that is reviewed by the independent DSMB. These data will include treatment comparisons of thromboembolic events and coagulation markers, and any additional data from studies carried out by Pfizer.
Intervention: NITROUS OXIDE
Trial phase: Phase 4
ATC code: N01AX13 | N01AX63
SMILES: [N-]=[N+]=O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 61
Group description: Patients will receive SANO in addition to periprostatic bupivacaine nerve block for the duration of prostate biopsy.

After the Urologist describes the procedure, the SANO group will have nitrous oxide turned on to 30%, ensuring that the patient is relaxed but still conversant through the procedure. The nitrous will be adjust up or down based on the patient's response to the question "are you feeling the nitrous" and "are you happy at this level". The range will be between 25 - 45%. At the end of the procedure, the SANO group will be turned down to 0% nitrous oxide, and 100% oxygen will be administered through the mask for an additional 2-3 minutes as the patient is cleaned up and repositioned to the supine position.

Self-Administered Nitrous Oxide: Nitrous oxide administered at concentrations of mild sedation (20-45%) for the duration of prostate biopsy.
Eligibility criteria:
Inclusion Criteria:

Biological male
Aged 18 to 85 years
Scheduled for clinically-indicated prostate needle biopsy
Suitable for nitrous oxide/oxygen with willingness to be randomized to inhaled SANO or inhaled oxygen during the procedure
Access to an email and computer

Exclusion Criteria:

Perioral facial hair impeding good mask seal
Learning disabilities and/or inability to cognitively complete survey questions
Taken a pre-procedure benzodiazepine or narcotic.

Has any of the following medical conditions:

Inner ear, bariatric or eye surgery within the last 2 weeks,
Current emphysematous blebs,
Severe B-12 deficiency.
Bleomycin chemotherapy within the past year.
Class III or higher heart failure.
Undergoing novel therapy for prostate cancer
Intervention: Fluvoxamine
Trial phase: Phase 3
ATC code: N06AB08
SMILES: COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 676
Group description: Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 10 days.

Fluvoxamine: Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has "APO" and the other side has "F50" with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.
Eligibility criteria:
Inclusion Criteria:

Completed Informed Consent
Age ≥ 30 years old
Confirmed SARS-CoV-2 infection by any authorized or approved polymerase chain reaction (PCR) or antigen test collected within 10 days of screening
Two or more current symptoms of acute infection for ≤7 days. Symptoms include the following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell

Exclusion Criteria:

Prior diagnosis of COVID-19 infection (> 10 days from screening)
Current or recent (within 10 days of screening) hospitalization
Known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo
Known contraindication(s) to study drug including prohibited concomitant medications
Intervention: Fluvoxamine
Trial phase: Phase 3
ATC code: N06AB08
SMILES: COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 589
Group description: Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 1 day, followed by a dose of 100 mg twice a day for 12 days.

Fluvoxamine: Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has "APO" and the other side has "F50" with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.
Eligibility criteria:
Inclusion Criteria:

Completed Informed Consent
Age ≥ 30 years old
Confirmed SARS-CoV-2 infection (or reinfection) by any authorized or approved polymerase chain reaction (PCR) or antigen test collected within 10 days of screening
Two or more current symptoms of acute infection for ≤7 days. Symptoms include the following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell

Exclusion Criteria:

Prior diagnosis of COVID-19 infection (> 10 days from screening)
Current or recent (within 10 days of screening) hospitalization
Known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo
Known contraindication(s) to study drug including prohibited concomitant medications

Additional Appendix-Level Exclusion Criteria

Use of selective serotonin (or norepinephrine) reuptake inhibitors (SSRIs/SNRIs), including fluvoxamine, or monoamine oxidase inhibitors (MAOIs) within 2 weeks of consent including triptans and tryptophan. Use of fluoxetine within 45 days of consent.
Co-administration of tizanidine, thioridazine, alosetron, pimozide, diazepam, ramelteon, linezolid
Bipolar Disorder
Nursing mothers
Pregnancy